Diamond Ranch Foods (PLPL) 0.2415 $PLPL
Plandai Biotechnology, Inc. Secures Collaboration Agreement to Further Company's Cannabis Research in Uruguay
Marketwired - Mon Jan 26, 8:03AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that its wholly-owned Uruguay subsidiary has executed a research agreement with the Foundation for the Development of Basic Sciences ("FUNDACIBA" and the Group of Medicinal Chemistry ("GQM" from the School of Science at the University of the Republic in Montevideo, Uruguay.
Plandai Biotechnology to Use "Trojan Horse" to Make Highly Bioavailable Products Even Stronger
Marketwired - Tue Jan 20, 8:05AM CST
Plandaà Biotechnology (OTCQB: PLPL) proved in a bioavailability study performed at North West University in South Africa, that its green tea Phytofare® Catechin Complex demonstrates ten times greater bioavailability over that of a generic catechin extract. Bioavailability is a fancy word for how much of the dosage of a drug or substance like PlandaÃ's extract gets absorbed into our bloodstream so it can actually be effective. The three-part human clinical trial proved in part two of the study that all 8 catechins that make up the green tea plant made it into the bloodstream of the 26 participants, and those catechins stayed in the bloodstream 5 times longer than the generic extract that PlandaÃ's product was compared to in the study.
Plandai Biotechnology, Inc.'s CEO Discusses Company's Plans for 2015
Marketwired - Fri Jan 09, 8:00AM CST
Plandaà Biotechnology (OTCQB: PLPL) recently updated shareholders on a list of accomplishments reached in 2014, so Stock Market Media Group (SMMG), a research and content development investment relations firm, spoke with PlandaÃ's Chief Executive Officer, Roger Duffield, to discuss PlandaÃ's plans for 2015.
Plandai Biotechnology, Inc. Provides Year-End Shareholder Update
Marketwired - Wed Dec 31, 8:00AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today provided an update to shareholders that reviews the company's accomplishments over the preceding twelve months.
Plandai Biotechnology, Inc. Announces Completion of $13 Million Production Facility
Marketwired - Mon Dec 22, 8:01AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company" , a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced completion of the Company's production facility in South Africa. Further, the Company announced that samples from the first batch of Phytofare® Catechin Complex, which is derived from green tea, are being delivered to testing facilities for final profiling which will take place once vendors return from holiday. Additionally, samples are being sent to North West University to complete their clinical trials and to potential customers for evaluation. Over the coming days the factory will increase its manufacturing production with the expectation that the Company will then be ready to accept and fill customer orders.
Plandai Biotechnology wins halaal certification for Senteeko facility in South Africa
M2 - Mon Dec 15, 6:12AM CST
Health plant extracts company Plandai Biotechnology (OtherOTC
LPL) revealed on Friday the receipt of the halaal certification for its Senteeko production facility in South Africa.
Plandai Biotechnology, Inc. Receives Halaal Certification for Senteeko Facility
Marketwired - Fri Dec 12, 8:00AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company" , a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Green Gold Biotechnologies Inc., a South African subsidiary of Plandaà which runs the Senteeko production facility, has received Halaal Certification in South Africa. Halaal certification is the process that food producers undergo to establish that they are producing products in accordance with Islamic Law and is seen as a necessary step before shipments can commence to various parts of the world.
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06)
Uruguay's Presidential Election Favors Plandai Biotechnology's Future Cannabis Research
Marketwired - Thu Dec 04, 8:06AM CST
Timing is everything and when Plandaà Biotechnology (OTCQB: PLPL) was given the go-ahead to grow cannabis for medical research in Uruguay, little did they know then that a Presidential runoff in that country would be of great interest today. Plandaà got the green light back in September from Uruguay's Minister of Public Health to collaborate with the Group of Medicinal Chemistry from the School of Science at the University of the Republic in Montevideo.
Plandai Biotechnology, Inc. Highlighted in Newly Published Article by South Africa's Department of Science & Technology
Marketwired - Mon Dec 01, 8:03AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company" , a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that the Company has been highlighted in an article titled "'Secret' Technology Turns Local Farm into Green Tea Extract Factory" in the December edition of the Republic of South Africa's Department of Science & Technology: Public Understanding of Biotechnology Newsletter. The article, which was reviewed by independent experts through the South African Agency for Science and Technology Advancement (SAASTA) Scientific Editorial Process, can be found at: http://www.pub.ac.za/newsletter/02-201412/article-1.html.
Plandai Biotechnology Could Offer Potential Anti-Viral Protection With Phytofare(TM) Catechin Complex Entrapped in Pheroid(R)
Marketwired - Tue Nov 18, 11:27PM CST
Plandaà Biotechnology (OTCQB: PLPL) entered into an agreement late last year with North West University in South Africa, that will allow it to use the Pheroid® technology to further increase bioavailability in its products. This enhanced bioavailability allows Plandaà to offer a potential solution for many possible viral and infectious diseases.
Plandai Biotechnology Collaboration Offers Opportunity to Produce a Non-Psychoactive Cannabis Product for Medical Research
Marketwired - Mon Nov 10, 8:06AM CST
Plandaà Biotechnology (OTCQB: PLPL) has entered into a collaboration agreement in Uruguay that will give the company the potential to produce a cannabis product with no psychoactive effects. If successful, the company could then move forward with medical research investigating whether or not the product is efficacious in areas like cancer, post-traumatic stress disorder, concussions, epilepsy, concussions, multiple sclerosis, and neural diseases like Alzheimer's and Parkinson's.
Plandai Biotechnology Cannabis Research Gets Green Light From Uruguay
Marketwired - Wed Nov 05, 8:04AM CST
Plandaà Biotechnology (OTCQB: PLPL) just became one of very few companies to receive a government sanction to grow cannabis for medical research. It was announced last week that Uruguay's Minister of Public Health has given Plandaà the go-ahead to collaborate with the Group of Medicinal Chemistry from the School of Science at the University of the Republic in Montevideo.
Plandai Biotechnology, Inc. Receives Approval to Grow Cannabis for Medical Research From Uruguay's Ministry of Public Health
Marketwired - Wed Oct 29, 8:08AM CDT
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company" , a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Uruguay's Ministry of Public Health has approved an academic collaboration between Plandaà and the Group of Medicinal Chemistry from the School of Science at the University of the Republic ("University" in Montevideo, Uruguay. The approval, issued in September 2014, allows Plandaà to grow cannabis in conjunction with the University, for medical research, which will be undertaken by students and scientists from the School of Science at the University.
Plandai Biotechnology's Technology Could Prove Potent in Battling Alzheimers Disease
Marketwired - Tue Oct 21, 8:10AM CDT
In the recently released preliminary results from Plandaà Biotechnology's (OTCQB: PLPL) human clinical trial that compared its green tea extract to a commercially available extract, Professor Anne Grobler and her team at North West University in South Africa proved that all 8 catechins found in the green tea plant were absorbed into the bloodstream of those using Phytofare(TM) Catechin Complex, including, the most potent catechin of the eight, epigallocatechin-3-gallate or EGCG.
Plandai Biotechnology Marketing of First Product to Customers Should Be a Cinch With Proven Higher Bioavailability
Marketwired - Fri Oct 17, 8:02AM CDT
Plandaà Biotechnology (OTCQB: PLPL) began to lay out its initial plan this week explaining just how the company will get its first product, a green tea extract, into the hands of distributors once production begins at its facility in South Africa by the end of 2014. The company announced that it will first ship samples of its Phytofare(TM) Catechin Complex, to a list of potential customers worldwide. PlandaÃ's samples will be part of a package of information that will include the green tea product, brochures, a product profile, and most importantly, the preliminary results from a recent clinical trial, safety data, and stability data (shelf life).
Plandai Biotechnology, Inc. Announces Update on Factory and Expected Plan to Market First Phytofare(TM) Product
Marketwired - Wed Oct 15, 8:28AM CDT
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company" , a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that the final equipment optimization is nearing completion at the Company's production facility in South Africa. Once the factory is officially "on-line" and its opening is announced, shipments of the Company's first Phytofare(TM) product to potential customers should begin before the end of the year.
Plandai Biotechnology Expects Pfizer Viagra Patent Ruling Will Aid in Developing All-Natural Substitute to Treat Erectile Dysfunction
Marketwire - Mon Sep 29, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) has already begun cultivating and cloning the epimedium plants it recently acquired as part of its preliminary plans to develop and test what it anticipates will be an all-natural substitute for the widely popular erectile dysfunction (ED) drugs Viagra(R), Cialis(R) and Levitra(R).
Plandai Biotechnology Plans to Develop Extract to Enter Lucrative Erectile Dysfunction Market With All-Natural Substitute for Viagra(R)
Marketwire - Mon Sep 22, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently announced its preliminary plans to develop and test an all-natural Phytofare(TM) extract for erectile dysfunction (ED). With an ED market that brings in billions annually, it's not hard to figure out why Plandai would use its unique and proprietary extraction process to try to develop and test another possible extract -- this time providing an all-natural alternative to existing ED drugs like Viagra(R) and Cialis(R).
Plandai Biotechnology, Inc. to Develop All-Natural Phytofare(TM) Extract for Erectile Dysfunction
Marketwire - Wed Sep 17, 8:02AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the acquisition of a strain of epimedium with high levels of icariin, the primary active compound in herbal epimedium, to develop an all-natural Phytofare(TM) extract for erectile dysfunction for further testing with the expectation that the extract could be sold as an active ingredient to pharmaceutical and nutraceutical manufacturers.
Plandai Biotechnology, Inc. Secures Collaboration Agreement to Further Company's Cannabis Research in Uruguay
Marketwired - Mon Jan 26, 8:03AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that its wholly-owned Uruguay subsidiary has executed a research agreement with the Foundation for the Development of Basic Sciences ("FUNDACIBA" and the Group of Medicinal Chemistry ("GQM" from the School of Science at the University of the Republic in Montevideo, Uruguay. Plandai Biotechnology to Use "Trojan Horse" to Make Highly Bioavailable Products Even Stronger
Marketwired - Tue Jan 20, 8:05AM CST
Plandaà Biotechnology (OTCQB: PLPL) proved in a bioavailability study performed at North West University in South Africa, that its green tea Phytofare® Catechin Complex demonstrates ten times greater bioavailability over that of a generic catechin extract. Bioavailability is a fancy word for how much of the dosage of a drug or substance like PlandaÃ's extract gets absorbed into our bloodstream so it can actually be effective. The three-part human clinical trial proved in part two of the study that all 8 catechins that make up the green tea plant made it into the bloodstream of the 26 participants, and those catechins stayed in the bloodstream 5 times longer than the generic extract that PlandaÃ's product was compared to in the study.
Plandai Biotechnology, Inc.'s CEO Discusses Company's Plans for 2015
Marketwired - Fri Jan 09, 8:00AM CST
Plandaà Biotechnology (OTCQB: PLPL) recently updated shareholders on a list of accomplishments reached in 2014, so Stock Market Media Group (SMMG), a research and content development investment relations firm, spoke with PlandaÃ's Chief Executive Officer, Roger Duffield, to discuss PlandaÃ's plans for 2015.
Plandai Biotechnology, Inc. Provides Year-End Shareholder Update
Marketwired - Wed Dec 31, 8:00AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today provided an update to shareholders that reviews the company's accomplishments over the preceding twelve months.
Plandai Biotechnology, Inc. Announces Completion of $13 Million Production Facility
Marketwired - Mon Dec 22, 8:01AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced completion of the Company's production facility in South Africa. Further, the Company announced that samples from the first batch of Phytofare® Catechin Complex, which is derived from green tea, are being delivered to testing facilities for final profiling which will take place once vendors return from holiday. Additionally, samples are being sent to North West University to complete their clinical trials and to potential customers for evaluation. Over the coming days the factory will increase its manufacturing production with the expectation that the Company will then be ready to accept and fill customer orders. Plandai Biotechnology wins halaal certification for Senteeko facility in South Africa
M2 - Mon Dec 15, 6:12AM CST
Health plant extracts company Plandai Biotechnology (OtherOTC
LPL) revealed on Friday the receipt of the halaal certification for its Senteeko production facility in South Africa. Plandai Biotechnology, Inc. Receives Halaal Certification for Senteeko Facility
Marketwired - Fri Dec 12, 8:00AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Green Gold Biotechnologies Inc., a South African subsidiary of Plandaà which runs the Senteeko production facility, has received Halaal Certification in South Africa. Halaal certification is the process that food producers undergo to establish that they are producing products in accordance with Islamic Law and is seen as a necessary step before shipments can commence to various parts of the world. American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06)
Uruguay's Presidential Election Favors Plandai Biotechnology's Future Cannabis Research
Marketwired - Thu Dec 04, 8:06AM CST
Timing is everything and when Plandaà Biotechnology (OTCQB: PLPL) was given the go-ahead to grow cannabis for medical research in Uruguay, little did they know then that a Presidential runoff in that country would be of great interest today. Plandaà got the green light back in September from Uruguay's Minister of Public Health to collaborate with the Group of Medicinal Chemistry from the School of Science at the University of the Republic in Montevideo.
Plandai Biotechnology, Inc. Highlighted in Newly Published Article by South Africa's Department of Science & Technology
Marketwired - Mon Dec 01, 8:03AM CST
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that the Company has been highlighted in an article titled "'Secret' Technology Turns Local Farm into Green Tea Extract Factory" in the December edition of the Republic of South Africa's Department of Science & Technology: Public Understanding of Biotechnology Newsletter. The article, which was reviewed by independent experts through the South African Agency for Science and Technology Advancement (SAASTA) Scientific Editorial Process, can be found at: http://www.pub.ac.za/newsletter/02-201412/article-1.html. Plandai Biotechnology Could Offer Potential Anti-Viral Protection With Phytofare(TM) Catechin Complex Entrapped in Pheroid(R)
Marketwired - Tue Nov 18, 11:27PM CST
Plandaà Biotechnology (OTCQB: PLPL) entered into an agreement late last year with North West University in South Africa, that will allow it to use the Pheroid® technology to further increase bioavailability in its products. This enhanced bioavailability allows Plandaà to offer a potential solution for many possible viral and infectious diseases.
Plandai Biotechnology Collaboration Offers Opportunity to Produce a Non-Psychoactive Cannabis Product for Medical Research
Marketwired - Mon Nov 10, 8:06AM CST
Plandaà Biotechnology (OTCQB: PLPL) has entered into a collaboration agreement in Uruguay that will give the company the potential to produce a cannabis product with no psychoactive effects. If successful, the company could then move forward with medical research investigating whether or not the product is efficacious in areas like cancer, post-traumatic stress disorder, concussions, epilepsy, concussions, multiple sclerosis, and neural diseases like Alzheimer's and Parkinson's.
Plandai Biotechnology Cannabis Research Gets Green Light From Uruguay
Marketwired - Wed Nov 05, 8:04AM CST
Plandaà Biotechnology (OTCQB: PLPL) just became one of very few companies to receive a government sanction to grow cannabis for medical research. It was announced last week that Uruguay's Minister of Public Health has given Plandaà the go-ahead to collaborate with the Group of Medicinal Chemistry from the School of Science at the University of the Republic in Montevideo.
Plandai Biotechnology, Inc. Receives Approval to Grow Cannabis for Medical Research From Uruguay's Ministry of Public Health
Marketwired - Wed Oct 29, 8:08AM CDT
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Uruguay's Ministry of Public Health has approved an academic collaboration between Plandaà and the Group of Medicinal Chemistry from the School of Science at the University of the Republic ("University" in Montevideo, Uruguay. The approval, issued in September 2014, allows Plandaà to grow cannabis in conjunction with the University, for medical research, which will be undertaken by students and scientists from the School of Science at the University. Plandai Biotechnology's Technology Could Prove Potent in Battling Alzheimers Disease
Marketwired - Tue Oct 21, 8:10AM CDT
In the recently released preliminary results from Plandaà Biotechnology's (OTCQB: PLPL) human clinical trial that compared its green tea extract to a commercially available extract, Professor Anne Grobler and her team at North West University in South Africa proved that all 8 catechins found in the green tea plant were absorbed into the bloodstream of those using Phytofare(TM) Catechin Complex, including, the most potent catechin of the eight, epigallocatechin-3-gallate or EGCG.
Plandai Biotechnology Marketing of First Product to Customers Should Be a Cinch With Proven Higher Bioavailability
Marketwired - Fri Oct 17, 8:02AM CDT
Plandaà Biotechnology (OTCQB: PLPL) began to lay out its initial plan this week explaining just how the company will get its first product, a green tea extract, into the hands of distributors once production begins at its facility in South Africa by the end of 2014. The company announced that it will first ship samples of its Phytofare(TM) Catechin Complex, to a list of potential customers worldwide. PlandaÃ's samples will be part of a package of information that will include the green tea product, brochures, a product profile, and most importantly, the preliminary results from a recent clinical trial, safety data, and stability data (shelf life).
Plandai Biotechnology, Inc. Announces Update on Factory and Expected Plan to Market First Phytofare(TM) Product
Marketwired - Wed Oct 15, 8:28AM CDT
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that the final equipment optimization is nearing completion at the Company's production facility in South Africa. Once the factory is officially "on-line" and its opening is announced, shipments of the Company's first Phytofare(TM) product to potential customers should begin before the end of the year. Plandai Biotechnology Expects Pfizer Viagra Patent Ruling Will Aid in Developing All-Natural Substitute to Treat Erectile Dysfunction
Marketwire - Mon Sep 29, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) has already begun cultivating and cloning the epimedium plants it recently acquired as part of its preliminary plans to develop and test what it anticipates will be an all-natural substitute for the widely popular erectile dysfunction (ED) drugs Viagra(R), Cialis(R) and Levitra(R).
Plandai Biotechnology Plans to Develop Extract to Enter Lucrative Erectile Dysfunction Market With All-Natural Substitute for Viagra(R)
Marketwire - Mon Sep 22, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently announced its preliminary plans to develop and test an all-natural Phytofare(TM) extract for erectile dysfunction (ED). With an ED market that brings in billions annually, it's not hard to figure out why Plandai would use its unique and proprietary extraction process to try to develop and test another possible extract -- this time providing an all-natural alternative to existing ED drugs like Viagra(R) and Cialis(R).
Plandai Biotechnology, Inc. to Develop All-Natural Phytofare(TM) Extract for Erectile Dysfunction
Marketwire - Wed Sep 17, 8:02AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the acquisition of a strain of epimedium with high levels of icariin, the primary active compound in herbal epimedium, to develop an all-natural Phytofare(TM) extract for erectile dysfunction for further testing with the expectation that the extract could be sold as an active ingredient to pharmaceutical and nutraceutical manufacturers.
